EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)

被引：0
|
作者：
Verma, S. [1 ]
Zielinski, C. [2 ]
Martin, M. [3 ]
机构：
[1] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[2] Med Univ Vienna, Vienna, Austria
[3] Hosp Clin Univ San Carlos, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [1] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [2] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [4] Intrathecal Catheter for Chemotherapy in Leptomeningeal Carcinomatosis From HER2-Negative Metastatic Breast Cancer
    Dupoiron, Denis
    Autier, Lila
    Lebrec, Nathalie
    Seegers, Valerie
    Folliard, Caroline
    Patsouris, Anne
    Campone, Mario
    Augereau, Paule
    JOURNAL OF BREAST CANCER, 2023, 26 (06) : 572 - 581
  • [5] Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
    Wan, Guoxing
    Cao, Fengjun
    Wang, Xuanbin
    Sun, Xue
    JOURNAL OF CANCER, 2019, 10 (02): : 416 - 417
  • [6] Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
    Kuemmel, S.
    Jackisch, C.
    Mueller, V.
    Schneeweiss, A.
    Klawitter, S.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Primary endpoints in first-line trials in patients with HER2-negative/-unknown metastatic breast cancer (MBC)
    Kuemmel, S.
    Mueller, V
    Lux, M. P.
    Weyer, G.
    Pintoffl, J. P.
    Jackisch, C.
    ONKOLOGIE, 2012, 35 : 66 - +
  • [8] New ASCO Guideline on HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03)
  • [9] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Reddy, Sangeetha
    Emens, Leisha A.
    Overmoyer, Beth
    Lange, Paulina
    Dilullo, Molly K.
    Attaya, Victoria
    Kimmel, Jeffrey
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Current approaches to the management of Her2-negative metastatic breast cancer
    Gogineni, Keerthi
    DeMichele, Angela
    BREAST CANCER RESEARCH, 2012, 14 (02)
12345